采用结构化治疗中断策略来控制HIV-1并限制药物暴露。

Structured treatment interruptions to control HIV-1 and limit drug exposure.

作者信息

Montaner L J

机构信息

The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.

出版信息

Trends Immunol. 2001 Feb;22(2):92-6. doi: 10.1016/s1471-4906(00)01809-3.

DOI:10.1016/s1471-4906(00)01809-3

PMID:11286710

Abstract

Although therapy-mediated suppression of HIV-1 is effective and results in a degree of immune reconstitution, the complications resulting from life-long treatment emphasize the need for alternatives. This review discusses the use of structured interruptions in antiviral therapy to induce drug-free periods of immune-mediated control of HIV-1. Such an approach has the ultimate objective of harnessing anti-viral immune responses, reducing drug exposure (toxicity and cost) and potentially extending the clinical benefits of a suppressive treatment regimen.

摘要

尽管治疗介导的HIV-1抑制是有效的，并能带来一定程度的免疫重建，但终身治疗所产生的并发症凸显了寻找替代方案的必要性。本综述讨论了在抗病毒治疗中使用结构化中断来诱导无药期的免疫介导的HIV-1控制。这种方法的最终目标是利用抗病毒免疫反应，减少药物暴露（毒性和成本），并有可能扩大抑制性治疗方案的临床益处。